Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) rose by 1.39% as of August 18, 2025, with notable gains from stocks such as Ascentage Pharma-B (06855) up 9.87% and Innovent Biologics (01801) also seeing an increase [3] - The Hong Kong Innovative Drug Select ETF (520690) increased by 2.15%, marking its fourth consecutive rise, with a latest price of 1.05 yuan [3] - The Hang Seng Healthcare Index (HSHCI) saw a 1.17% increase, with Ascentage Pharma-B (06855) again leading with a 9.87% rise [5] Group 2: Fund Performance and Liquidity - The Hong Kong Innovative Drug Select ETF had a turnover of 5.08% and a transaction volume of 20.86 million yuan, with an average daily transaction volume of 80.37 million yuan over the past week [3] - The Hang Seng Healthcare ETF (513060) experienced a turnover of 4.14% and a transaction volume of 328 million yuan, with a monthly average transaction volume of 2.65 billion yuan [5] - The Hong Kong Innovative Drug Select ETF's net inflow over the past five trading days totaled 15.81 million yuan, despite a recent net outflow of 2.04 million yuan [12] Group 3: Policy Developments - The National Healthcare Security Administration is currently publicizing the list of drugs that have passed the preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," with the public comment period ending on August 18 [7] Group 4: Company Highlights - JD Health reported a revenue of 35.3 billion yuan for the first half of 2025, reflecting a year-on-year growth of 24.5%, with a Non-IFRS net profit of 3.57 billion yuan, up 35% [8] - Silver诺药业 debuted on the Hong Kong Stock Exchange on August 15, with an oversubscription of approximately 5,365 times, raising about 683 million HKD, and its stock price surged by 206.48% on the first day [9] Group 5: Investment Insights - The dual-track policy for medical insurance and commercial insurance for innovative drugs indicates a developing payment closure, suggesting that "true innovation is more likely to gain volume" [10] - The innovative drug sector is undergoing systematic re-evaluation, driven by the dual-track payment system and significant business development opportunities [10] - The Hang Seng Healthcare ETF has shown a net asset growth of 4.23 billion yuan over the past week, ranking first among comparable funds [16]
港股创新药精选ETF(520690)上涨2.15%,恒生医疗ETF(513060)冲击4连涨,中国创新药板块系统性重估仍在继续
Xin Lang Cai Jing·2025-08-18 02:02